Fine Organic Industries Limited — Q4 FY25 earnings call

Call held 12 May 2025

Management summary

Fine Organic delivered a steady performance in FY25 despite raw material and utility cost headwinds. The company is entering a significant expansion phase with a ₹750 crore SEZ project and its first overseas manufacturing plant in the US. While immediate volume growth is constrained by high capacity utilization, management is leveraging its strong cash position to secure long-term growth through strategic domestic and international investments.

Highlights

  • Revenue from operations grew 6.9% YoY to ₹2,269 crores in FY25.

  • EBITDA stood at ₹512.9 crores, a decline of 4% YoY, with margins at 22.6%.

  • PAT remained nearly flat at ₹410.5 crores compared to ₹411.9 crores in FY24.

  • Domestic and export businesses contributed 43% and 57% of total revenue respectively.

  • Announced a major capex of ₹700-750 crores for a new SEZ facility at JNPA, Maharashtra.

  • Planned global expansion with new manufacturing entities in the United States and a subsidiary in the UAE.

  • Cash and bank balance remains robust at approximately ₹1,150-1,200 crores.

  • Most existing plants are running at near-full capacity, with incremental growth expected from the Patalganga (E-73) unit.

Concerns

  • Capacity Saturation

Key financials

  1. Revenue ₹2,269 Cr +6.9%YoY
  2. EBITDA ₹512.9 Cr -4%YoY
  3. EBITDA Margin 22.6%
  4. PAT ₹410.5 Cr -0.3%YoY
  5. Consolidated Capex ₹125 Cr

What they filed

Q1 FY27: revenue up 19.5%, net profit up 46.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue595 522 576 559 572 −4%529 +1%616 +7%668 +19%
EBITDA143 104 108 107 108 −24%85 −18%111 +3%173 +62%
Net profit113 89 89 93 95 −16%68 −24%90 +1%136 +46%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Domestic Business
    43% Revenue Contribution
  • Export Business
    57% Revenue Contribution

Guidance & targets

Capex

  • JNPA SEZ Facility Total Capex Capex · Next 24 months · High confidence ₹700-750 crores
    But we have already announced total is going to be around INR700 crores, INR750 crores, somewhere in between.

    — Mukesh Shah, Chairman

Capacity

  • JNPA SEZ Construction Timeline Capacity · FY27 · High confidence 18-24 months
    As previously mentioned, construction will commence soon and is expected to be completed within 18 to 24 months.

    — Mukesh Shah, Chairman

  • Patalganga (E-73) Utilization Capacity · H1 FY27 · Medium confidence 100%
    And I think by March FY '26 or latest by first half of '27, this is also going to get full.

    — Mukesh Shah, Chairman

Volume

  • India Volume Growth CAGR Volume · Long-term · Medium confidence 8-10%
    But in India it is a little bit higher, maybe 8% to 10%.

    — Mukesh Shah, Chairman

Market context

  • Global Volume Growth CAGR Volume · Long-term · Medium confidence 5-6%
    Yes. Globally -- you can say that all products together average 5% to 6% is okay globally.

    — Mukesh Shah, Chairman

Risks & concerns

  • Capacity Saturation

    high

    Most plants are running full, limiting the ability to onboard large new accounts until the JNPA facility is operational in ~2 years.

    Both acknowledged

  • Raw Material Price Volatility

    medium

    Raw material prices saw an upward trend from Q2 to Q4 FY25, impacting margins on long-term contracts where costs couldn't be passed through immediately.

    Management acknowledged

  • Execution Risk in US Market

    medium

    First-time manufacturing in the US involves regulatory, labor, and cultural risks that management is mitigating through a conservative Phase 1 capacity.

    Both acknowledged

Areas of evasion (3)

  • Ballpark revenue loss from the fire incident
  • Specific margin profile for US operations
  • Specific timeline for US Phase 1 commissioning

Q&A highlights

2 direct, 1 evasive
Revenue Loss from Fire Incident Evasive
I think it would not be right to say those things, but...

Investors were looking to quantify the impact of the Badlapur plant shutdown on FY25 performance and the potential recovery from insurance claims.

Asked by Arun Prasath, Avendus Spark

Capacity Constraints for Next 2 Years Direct
I cannot take any big account, new account till we have additional capacity. So till we will have to continue meeting the demands of the existing customers first.

Reveals a potential growth plateau for the next 24 months as the company is prioritizing existing clients over new business due to lack of spare capacity.

Asked by Jasdeep, Clockvine Capital

Risks of US Manufacturing Expansion Direct
We are a little bit cautious because we don't have experience of running the plant in U.S. with U.S. regulations and U.S. systems... The local people from India will not be helpful because the culture there is totally different.

Management acknowledges the steep learning curve and cultural challenges of their first major Western manufacturing foray.

Asked by Aatur, ICICI Prudential Mutual Funds

2 min read 5 chapters

Detailed narrative

Strategic Pivot to SEZ and US Manufacturing

Fine Organic is undertaking its most ambitious expansion phase yet, centered on a new ₹700-750 crore facility in the JNPA SEZ. This facility is designed to cater primarily to international markets, which will free up existing domestic capacity to meet strong local demand. Simultaneously, the company is establishing its first US manufacturing base with an initial equity infusion of ₹45 crores. Management believes local US production is essential to capture a larger wallet share from major clients who currently face 2-3 month lead times for Indian exports.

Capacity Constraints and Growth Outlook

A key takeaway from the call is that Fine Organic is currently operating at near-full capacity across almost all units except the Patalganga (E-73) plant. This plant, which started in March 2022, is expected to reach full utilization by H1 FY27. Consequently, management expects only 'little growth' in volumes over the next two years until the JNPA facility comes online. The company is currently prioritizing existing customers and is unable to onboard significant new accounts, suggesting a temporary plateau in volume growth.

Margin Pressures and Cost Dynamics

FY25 EBITDA margins stood at 22.6%, impacted by a 'notable upward trend' in raw material prices starting from Q2. While the company successfully passed on costs in short-term contracts, it had to absorb higher input costs for long-term (typically 1-year) contracts. Utility costs also rose due to higher per-unit energy prices and increased production volumes. However, logistics costs began to normalize in the second half of the year as global shipping bottlenecks eased.

Robust Liquidity and Capital Allocation

The company maintains a very strong balance sheet with total cash and investments of approximately ₹1,150 to ₹1,200 crores. This includes ₹200 crores recently moved into long-term fixed deposits. This liquidity will be used to fund the JNPA and US expansions through a mix of internal accruals and debt. Management also indicated they are keeping 'spare cash' available for potential M&A opportunities that may arise in complementary product lines.

Operational Recovery and Specialty Focus

The Badlapur manufacturing unit resumed full operations in Q3 FY25 after a temporary shutdown due to a fire at an adjacent facility. In Thailand, the company has started trial production of super-specialty products and is awaiting Thai FDA approvals for commercial ramp-up. Management emphasized that they are moving away from commodity products toward more complex, technical additives where they hold a competitive edge over larger, older global peers.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls